查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827986

活细胞封装市场（按应用、技术、材料、最终用户和细胞类型）—2025-2032 年全球预测

Live Cell Encapsulation Market by Application, Technology, Material, End User, Cell Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年活细胞封装市场规模将成长至 4.6656 亿美元，复合年增长率为 4.58%。

主要市场统计数据
基准年2024年 3.2589亿美元
预计2025年 3.4117亿美元
预测年份：2032年 4.6656亿美元
复合年增长率（%） 4.58%

简要介绍技术、应用和临床需求，为活细胞封装的突破奠定基础

活细胞封装技术是材料科学、细胞治疗和医疗设备工程的交叉领域，为保护、维持和控制治疗细胞的生物活性提供了一种突破性的方法。从根本上讲，封装技术将活细胞置于半透性屏障内，保护细胞免受免疫排斥和机械应力的影响，同时允许营养物质和废物的交换。这项技术前提已促进了肿瘤学、代谢疾病、药物传递和组织修復等领域的应用，将这一概念从实验室示范推进到转化医学发展。

近年来，聚合物化学、微加工技术和细胞获取技术的进步，拓展了封装细胞疗法的功能范围和转化可行性。监管机构对製剂的期望日益明确，临床项目也从概念验证转向长期安全性和有效性评估。因此，产业相关人员正在探索多种商业化途径，从局部组织工程构建体到提供内分泌和免疫调节功能的植入式装置。

鑑于这些动态，清晰的策略对于相关人员至关重要。开发商必须同时优先考虑材料相容性、可製造性和监管策略，而投资者和合作伙伴则必须根据技术差异评估临床风险。本介绍概述了将资源集中在封装上的技术和商业性原理，为后续章节中更深入地讨论市场驱动因素、细分市场和营运考虑奠定了基础。

透过科学进步、监管变化和跨学科合作，识别重塑活细胞封装的变革性转变

一系列相互依存的变革正在重新定义机会和风险，活细胞封装的模式正在迅速改变。封装材料和微加工技术的科学进步正在提高耐用性和细胞活力，使其能够长期发挥作用，并扩大潜在适应症。同时，细胞来源的改进，尤其是可再生细胞衍生产品和细胞株工程的进步，正在降低差异性，并扩大可封装的治疗有效载荷的范围。

同时，法律规范也在不断发展，以适应组合产品和生物材料-器械接口，这加速了开发商和监管机构之间的对话，并提高了临床前安全数据、生产控制和清晰的效益-风险描述的重要性。在商业性方面，付款人和医疗保健系统要求提供持续临床效益和成本效益的证据，并将开发重点转向能够展现有意义的患者疗效和健康经济价值的终点。

这些技术、监管和商业性变革，加上供应链物流、品管系统和数位化製造的进步，使得许多开发商能够实现先前遥不可及的规模扩张。因此，该行业正变得越来越分化：一方面是能够自主管理电池采购、封装和製造的垂直整合公司，另一方面是专注于材料、设备以及合约开发和製造服务的专业供应商。这种转变有利于那些能够将技术差异化与严谨的监管和商业化策略结合的组织。

评估 2025 年美国关税对活细胞封装供应链、零件成本和策略采购的累积影响

2025年征收关税和贸易政策转变将对活细胞封装生态系统产生累积累积，改变进口零件的经济性，推动采购变革，并凸显供应链的脆弱性。许多封装系统依赖全球采购的专用聚合物、试剂、医疗器材和精密仪器。对投入品征收关税可能会增加到岸成本，从而压缩製造商、合约供应商和最终用户的计划预算和决策点。

为了应对这项挑战，企业正在加快关键供应链的本地化进程，例如筛选合格的国内供应商、跨地区双重采购原材料，或鼓励上游供应商将生产基地设在更靠近製造地的地方。这一趋势会影响前置作业时间、库存策略以及扩大规模所需的资本配置。一些开发商正在协商长期供应协议并建立联合生产伙伴关係关係，以减轻关税的影响并保持其临床项目的连续性。

除了成本影响之外，关税还促使企业重新评估产品设计和材料清单，包括转向贸易摩擦较少的材料和零件。战略应对措施还包括在法律允许的情况下利用贸易优惠计划、保税仓库和关税工程等关税缓解机制。总而言之，2025年的关税格局强调了灵活的筹资策略和早期供应链整合在封装细胞疗法商业化计画中的重要性。

关键细分洞察阐明了跨应用、技术、材料、最终用户和细胞类型的价值路径，有助于策略决策

细緻的细分框架清楚地阐明了在活细胞封装领域，技术投入和商业性重点将在哪些领域产生最高回报。按应用领域划分，该领域包括细胞疗法、糖尿病管理、药物传输和组织工程。在细胞疗法领域，开发人员专注于癌症免疫疗法和再生疗法；而在糖尿病管理计画中，他们区分胰岛素分泌细胞传递和胰岛细胞移植。药物输送分为控制释放和标靶输送，而组织工程涵盖骨、心臟和软骨组织工程。这些不同的应用对设备几何形状、免疫隔离性能和临床终点提出了不同的要求。

目录

第一章 引言

第二章分析方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 整合微流体液滴生成技术，实现可扩展的细胞封装，增强均匀性和活力
  • 富含 RGD 胜肽的藻酸盐基水凝胶调变器的出现改善了封装细胞的分化和功能。
  • 采用 3D 生物列印技术製造可客製化的含细胞胶囊，用于靶向药物传输和组织工程
  • 引入免疫逃脱聚合物涂层来延长封装胰岛细胞的体内存活时间，用于治疗糖尿病
  • 开发感测器整合封装系统，可以即时监测细胞微环境和代谢状态
  • 采用结合干细胞和生长因子奈米粒子的共封装策略可提供协同再生效应。
  • 促进标准化品管检测法规，确保封装细胞产品批次间性能的一致性
  • 人们对无冷冻保护剂封装工作流程的兴趣日益浓厚，以提高细胞疗法解冻后的活力
  • 开发可扩展的生物反应器平台，用于高通量生产携带治疗细胞的微胶囊
  • 将人工智慧主导的流程最佳化整合到您的封装工作流程中，以提高可重复性和扩充性。

第六章：美国关税的累积影响（2025年）

第七章：人工智慧（AI）的累积影响（2025年）

第八章活细胞封装市场（依应用）

  • 细胞疗法
    • 癌症免疫治疗
    • 再生疗法
  • 糖尿病管理
    • 输送至胰岛素产生细胞
    • 胰岛细胞移植
  • 药物输送
    • 控释
    • 靶向药物输送
  • 组织工程
    • 骨组织工程
    • 心臟组织工程
    • 软骨组织工程

9. 活细胞封装市场（依技术）

  • 大分子胶囊化
    • 中空纤维装置
    • 水凝胶片
  • 微胶囊化
    • 乳化技术
    • 挤压成型技术
    • 喷雾干燥

第 10 章活细胞封装市场（依材料）

  • 藻酸盐
    • 高胶凝海藻酸盐
    • 低胶凝海藻酸盐
  • 几丁聚醣
    • 交联几丁聚醣
    • 去乙酰几丁聚醣
  • 胶原蛋白
  • 合成聚合物

第 11 章。活细胞封装市场（依最终用户）

  • 生技公司
  • 医院和诊所
  • 製药公司
  • 研究机构

第 12 章活细胞封装市场（依细胞类型）

  • 胰岛细胞
    • 供体胰岛细胞
    • 干细胞衍生的胰岛细胞
  • 益生菌
    • 双歧桿菌
    • 乳酸菌
  • 干细胞
    • 诱导性多功能细胞
    • 间质干细胞

第十三章活细胞封装市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章活细胞封装市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。活细胞封装市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 市占率分析（2024年）
  • FPNV定位矩阵（2024年）
  • 竞争分析
    • AUSTRIANOVA
    • Merck KGaA
    • Sphere Fluidics Ltd.
    • ViaCyte, Inc.
    • Blacktrace Holdings Ltd.（Dolomite Microfluidics）
    • BIO INX
    • Living Cell Technologies Ltd.
    • Sigilon Therapeutics, Inc.
    • Isogen
    • Diatranz Otsuka Ltd.
    • Sernova Corporation
    • Atelerix Ltd.
    • Neurotech Pharmaceuticals
    • Kadimastem
    • BUCHI Labortechnik AG
    • Fluigent
    • Encapsys LLC
    • MiKroCaps
    • Reed Pacific Pty Limited
    • Lycored
Product Code: MRR-437517DB6D5D

The Live Cell Encapsulation Market is projected to grow by USD 466.56 million at a CAGR of 4.58% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 325.89 million
Estimated Year [2025] USD 341.17 million
Forecast Year [2032] USD 466.56 million
CAGR (%) 4.58%

Setting the stage for live cell encapsulation breakthroughs with a concise introduction to technologies, applications, and clinical imperatives

Live cell encapsulation stands at the intersection of materials science, cellular therapy, and medical device engineering, offering a transformative means to protect, sustain, and control the biological activity of therapeutic cells. At a basic level, encapsulation technologies enclose living cells within a semi-permeable barrier that permits nutrient and waste exchange while shielding cells from immune rejection or mechanical stress. This technical premise has catalyzed applications across oncology, metabolic disease, drug delivery, and tissue repair, transitioning the concept from laboratory demonstration to translational development.

Over recent years, advances in polymer chemistry, microfabrication, and cell sourcing have converged to expand both the functional scope and translational feasibility of encapsulated cell therapies. Regulatory agencies are increasingly clarifying expectations for combination products, and clinical programs are moving beyond proof-of-concept to longer-term safety and efficacy evaluation. Consequently, industry participants are progressing along multiple commercialization pathways-ranging from localized tissue engineering constructs to implantable devices delivering endocrine or immunomodulatory functions.

Given these dynamics, strategic clarity is essential for stakeholders. Developers must prioritize material compatibility, manufacturability, and regulatory strategy concurrently, while investors and partners evaluate clinical risk against technical differentiation. This introduction frames the technical and commercial rationale for focusing resources on encapsulation, and sets the stage for deeper discussion of market drivers, segmentation, and operational considerations contained in the subsequent sections.

Identifying transformative shifts reshaping live cell encapsulation driven by scientific advances, regulatory change, and cross-disciplinary collaboration

The live cell encapsulation landscape is changing rapidly due to a set of interdependent shifts that together redefine opportunity and risk. Scientific advances in encapsulation materials and microfabrication have increased durability and cell viability, enabling longer-term functionality and expanding potential indications. At the same time, improvements in cell sourcing-particularly renewable stem cell-derived products and improved cell-line engineering-reduce variability and expand the range of therapeutic payloads that can be encapsulated.

Concurrently, regulatory frameworks are evolving to address combination products and biomaterial-device interfaces, prompting earlier dialog between developers and regulators and raising the premium on preclinical safety data, manufacturing controls, and clear benefit-risk articulation. On the commercial side, payers and health systems demand evidence of durable clinical benefit and cost-effectiveness, reshaping development priorities toward endpoints that demonstrate meaningful patient outcomes and health economic value.

These technical, regulatory, and commercial shifts are amplified by advances in supply chain logistics, quality management systems, and digital manufacturing controls, which together enable scale-up pathways previously out of reach for many developers. As a result, the industry is seeing a stratification between vertically integrated players that can manage cell sourcing, encapsulation, and manufacturing in-house, and specialized suppliers that focus on materials, devices, or contract development and manufacturing services. This transformation favors organizations that combine technical differentiation with disciplined regulatory and commercialization strategies.

Assessing the cumulative impact of United States tariffs in 2025 on supply chains, component costs, and strategic sourcing for live cell encapsulation

The imposition of tariffs and trade policy shifts in 2025 has had a cumulative effect on the live cell encapsulation ecosystem by altering the economics of imported components, spurring sourcing changes, and highlighting supply chain vulnerabilities. Many encapsulation systems depend on specialized polymers, reagents, medical-grade equipment, and precision devices sourced globally. Tariffs on inputs can increase landed cost, which in turn pressures project budgets and decision points for manufacturers, contract providers, and end users.

In response, organizations have accelerated efforts to localize critical supply chains, either by qualifying domestic suppliers, dual sourcing materials across regions, or incentivizing upstream vendors to establish production close to manufacturing hubs. This trend has implications for lead times, inventory strategies, and capital allocation for scale-up; it also influences where clinical and manufacturing activities are concentrated. Some developers have negotiated longer-term supply agreements and engaged in collaborative manufacturing partnerships to mitigate tariff exposure and maintain continuity for clinical programs.

Beyond cost impacts, tariffs have encouraged careful re-evaluation of product design and bill of materials, including a shift toward materials and components that can be sourced with fewer trade frictions. Strategic responses also include leveraging tariff mitigation mechanisms such as trade preference programs, bonded warehousing, or tariff engineering where legally appropriate. In sum, the 2025 tariff landscape has reinforced the importance of resilient sourcing strategies and early supply chain integration in commercialization planning for encapsulated cell therapies.

Key segmentation insights that clarify value pathways across application, technology, material, end user, and cell type dimensions for strategic decision-making

A nuanced segmentation framework clarifies where technical effort and commercial focus will yield the highest returns in live cell encapsulation. Based on application, the field encompasses Cell Therapy, Diabetes Management, Drug Delivery, and Tissue Engineering; within Cell Therapy developers concentrate on Cancer Immunotherapy and Regenerative Therapy, while Diabetes Management programs differentiate between Insulin-Producing Cell Delivery and Islet Cell Transplantation. Drug Delivery efforts split between Controlled Release and Targeted Drug Delivery approaches, and Tissue Engineering initiatives target Bone Tissue Engineering, Cardiac Tissue Engineering, and Cartilage Tissue Engineering. These application distinctions drive divergent requirements for device geometry, immunoisolation performance, and clinical endpoints.

Based on technology, encapsulation solutions fall into Macroencapsulation and Microencapsulation. Macroencapsulation developers use approaches such as Hollow Fiber Devices and Hydrogel Sheets, prioritizing implantability and retrievability, while Microencapsulation leverages techniques like Emulsion Technique, Extrusion Technique, and Spray Drying to optimize mass transfer and cell packing density. Material selection is another critical axis: Alginate, Chitosan, Collagen, and Synthetic Polymer each present distinctive biocompatibility and manufacturing profiles, with Alginate variants categorized as High Gelation and Low Gelation and Chitosan available as Crosslinked and Deacetylated forms.

End user segmentation highlights the divergent needs of Biotechnology Companies, Hospitals & Clinics, Pharmaceutical Companies, and Research Institutes, influencing support services, regulatory expectations, and purchasing behaviors. Finally, cell type matters: Islet Cells are differentiated into Donor Islet Cells and Stem Cell Derived Islet Cells; Probiotic Bacteria include Bifidobacterium and Lactobacillus; Stem Cells break down into Induced Pluripotent Stem Cells and Mesenchymal Stem Cells. Together, these segmentation dimensions emphasize that commercial strategy must align material science, encapsulation technique, and clinical pathway to the chosen therapeutic application.

Regional dynamics and strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence adoption and commercialization

Regional dynamics shape adoption, regulatory strategy, and supply chain design for live cell encapsulation technologies. In the Americas, markets are characterized by strong venture capital activity, advanced clinical trial ecosystems, and a regulatory environment that emphasizes early sponsor-regulator interaction; this region often serves as a proving ground for clinical evidence and reimbursement models. Europe, Middle East & Africa presents a mosaic of regulatory regimes and health system structures, where alignment with regional regulatory bodies and payer evidence requirements is essential to broaden access across diverse markets. Asia-Pacific shows rapid investment in domestic manufacturing capacity, an expanding base of clinical centres, and government-led initiatives to foster biotech innovation, which together accelerate local development and commercial pathways.

These regional distinctions matter for market entry timing, partner selection, and manufacturing footprint. For example, a development program may choose to validate clinical endpoints and build health economic models in the Americas before pursuing broader regulatory harmonization in Europe, Middle East & Africa, while simultaneously engaging manufacturing partners in Asia-Pacific to reduce cost and shorten lead times. Trade policy, intellectual property frameworks, and public funding priorities vary by region, and successful players synchronize clinical development, supply chain resilience, and commercial launch sequencing to exploit regional strengths. In short, a deliberate regional strategy that leverages complementary advantages across the Americas, Europe, Middle East & Africa, and Asia-Pacific will materially improve scalability and access.

Profiles of leading companies, competitive positioning, and strategic moves shaping product development, partnerships, and commercialization in the live cell encapsulation arena

Company strategies in live cell encapsulation reveal a split between vertically integrated developers and specialized technology providers. Leading innovators invest in proprietary materials, device architectures, and process controls, positioning themselves to capture downstream value through product differentiation and integrated manufacturing. At the same time, a cohort of suppliers focuses on enabling components-high-purity polymers, encapsulation machinery, and contract development and manufacturing services-creating an ecosystem that reduces barriers to entry for clinical-stage developers.

Partnerships and collaborations are a commonplace strategic play. Biotech firms often enter co-development agreements with materials specialists or device manufacturers to accelerate translational timelines and de-risk technical challenges. Meanwhile, contract organizations are expanding capabilities to support aseptic processing, quality systems, and scale-up for combination product manufacturing. Competitive positioning is also shaped by intellectual property around encapsulation chemistries and microfabrication methods, and companies with defensible IP portfolios can secure advantageous licensing arrangements or investment.

Mergers and strategic alliances continue to consolidate capabilities, particularly where a partner can offer complementary strengths such as clinical development expertise, regulatory experience, or commercial distribution. For decision-makers, the landscape rewards clarity about where to invest internally versus where to partner, and encourages an early focus on manufacturability, regulatory alignment, and demonstrable clinical benefit to sustain competitive advantage.

Actionable recommendations for industry leaders to accelerate innovation, de-risk supply chains, and optimize clinical translation pathways in live cell encapsulation

Industry leaders should prioritize a set of actionable initiatives that reduce technical risk, strengthen supply chains, and accelerate clinical translation. First, diversify supplier relationships for critical materials and components while qualifying alternate sources and creating contingency inventory strategies to buffer against geopolitical and trade disruptions. Second, invest in material science efforts aimed at improving biocompatibility and mechanical stability to lengthen device lifetimes and reduce immune responses, thereby improving clinical outcomes and payer receptivity.

Third, engage regulators early with robust preclinical packages and clear manufacturing controls to shorten approval cycles and de-risk pivotal studies. Simultaneously, design clinical programs with endpoints that address patient-centered outcomes and health economic measures to facilitate reimbursement discussions. Fourth, pursue modular manufacturing strategies and digital quality systems to scale production efficiently and maintain traceability across cell-based processes. Fifth, build strategic partnerships with contract manufacturers and clinical trial networks to accelerate enrollment and reduce the time from bench to bedside.

Finally, adopt a proactive IP and commercialization playbook: protect core material and fabrication innovations while licensing or partnering where complementary capabilities exist. Together, these steps create a roadmap for organizations seeking to translate encapsulation innovations into durable products that satisfy regulators, payers, and clinicians alike.

Research methodology that underpins the analysis including data triangulation, stakeholder interviews, and validation protocols for credible live cell encapsulation insights

The research underpinning this analysis employed a multi-method approach combining qualitative and quantitative validation to ensure robustness and relevance. Primary research included structured interviews with senior executives, R&D leaders, regulatory experts, contract manufacturers, and clinical investigators to capture first-hand perspectives on technical barriers, commercialization challenges, and strategic priorities. Secondary sources comprised peer-reviewed literature, patent filings, clinical trial registries, regulatory guidance documents, and supplier catalogs to map technological evolution and identify enabling materials and processes.

Data triangulation was used to corroborate findings across independent sources, and a synthesis layer reconciled clinical, technical, and commercial inputs into actionable insights. The methodology also incorporated supply chain mapping to identify chokepoints and geographic dependencies, and a regulatory heatmap to align development pathways with region-specific requirements. Throughout the process, validation workshops with external experts refined interpretations and ensured practical applicability for decision-makers.

Limitations of the research are acknowledged, including the evolving nature of clinical data and the potential for rapid innovation to shift competitive dynamics. Nonetheless, the methodology emphasizes transparency, stakeholder validation, and reproducibility to provide a credible foundation for strategic decisions in live cell encapsulation.

Concluding synthesis that ties scientific, commercial, and regulatory threads into a coherent outlook for stakeholders engaged in live cell encapsulation

The synthesis presented in this report emphasizes that progress in live cell encapsulation is both technological and organizational. Technically, advances in materials, microfabrication, and cell sourcing are reducing historical barriers to durability and biocompatibility, enabling longer-term therapeutic effects. Organizationally, regulatory evolution, payer scrutiny, and supply chain reconfiguration are shaping which programs advance and which must pivot or consolidate. These dual forces determine the practical pathway to commercialization for encapsulated cell therapies.

Looking across segmentation, technology choices must be matched to application-specific clinical objectives and end-user needs, while regional strategies must balance clinical validation hubs with manufacturing pragmatism. Firms that align product design, material selection, and manufacturable processes with a clear regulatory and reimbursement plan are most likely to achieve sustainable clinical and commercial success. Moreover, the 2025 trade dynamics underscore the value of resilient sourcing and adaptive cost management in maintaining program continuity.

In conclusion, stakeholders should pursue disciplined technical validation, early regulatory engagement, and strategic partnerships to translate encapsulation innovations into therapies that demonstrate durable patient benefit. The path forward rewards integrated approaches that connect scientific differentiation with operational excellence and clear commercial value propositions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of microfluidic droplet generation techniques for scalable cell encapsulation to enhance uniformity and viability
  • 5.2. Emergence of alginate-based hydrogel modulators enriched with RGD peptides to improve cell differentiation and functionality in encapsulation
  • 5.3. Adoption of 3D bioprinting methods to fabricate customizable cell-laden capsules for targeted drug delivery and tissue engineering
  • 5.4. Implementation of immune-evasive polymer coatings to extend in vivo survival of encapsulated islet cells in diabetes therapy
  • 5.5. Development of sensor-integrated encapsulation systems enabling real-time monitoring of cell microenvironment and metabolic status
  • 5.6. Use of co-encapsulation strategies combining stem cells with growth factor-loaded nanoparticles for synergistic regenerative outcomes
  • 5.7. Regulatory momentum around standardized quality control assays for ensuring consistent batch-to-batch performance of encapsulated cell products
  • 5.8. Rising interest in cryoprotectant-free encapsulation workflows to improve post-thaw viability of cell therapies
  • 5.9. Development of scalable bioreactor platforms for high-throughput production of microcapsules carrying therapeutic cells
  • 5.10. Integration of artificial intelligence-driven process optimization in encapsulation workflows for enhanced reproducibility and scalability

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Live Cell Encapsulation Market, by Application

  • 8.1. Cell Therapy
    • 8.1.1. Cancer Immunotherapy
    • 8.1.2. Regenerative Therapy
  • 8.2. Diabetes Management
    • 8.2.1. Insulin-Producing Cell Delivery
    • 8.2.2. Islet Cell Transplantation
  • 8.3. Drug Delivery
    • 8.3.1. Controlled Release
    • 8.3.2. Targeted Drug Delivery
  • 8.4. Tissue Engineering
    • 8.4.1. Bone Tissue Engineering
    • 8.4.2. Cardiac Tissue Engineering
    • 8.4.3. Cartilage Tissue Engineering

9. Live Cell Encapsulation Market, by Technology

  • 9.1. Macroencapsulation
    • 9.1.1. Hollow Fiber Devices
    • 9.1.2. Hydrogel Sheets
  • 9.2. Microencapsulation
    • 9.2.1. Emulsion Technique
    • 9.2.2. Extrusion Technique
    • 9.2.3. Spray Drying

10. Live Cell Encapsulation Market, by Material

  • 10.1. Alginate
    • 10.1.1. High Gelation Alginate
    • 10.1.2. Low Gelation Alginate
  • 10.2. Chitosan
    • 10.2.1. Crosslinked Chitosan
    • 10.2.2. Deacetylated Chitosan
  • 10.3. Collagen
  • 10.4. Synthetic Polymer

11. Live Cell Encapsulation Market, by End User

  • 11.1. Biotechnology Companies
  • 11.2. Hospitals & Clinics
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Institutes

12. Live Cell Encapsulation Market, by Cell Type

  • 12.1. Islet Cells
    • 12.1.1. Donor Islet Cells
    • 12.1.2. Stem Cell Derived Islet Cells
  • 12.2. Probiotic Bacteria
    • 12.2.1. Bifidobacterium
    • 12.2.2. Lactobacillus
  • 12.3. Stem Cells
    • 12.3.1. Induced Pluripotent Stem Cells
    • 12.3.2. Mesenchymal Stem Cells

13. Live Cell Encapsulation Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Live Cell Encapsulation Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Live Cell Encapsulation Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AUSTRIANOVA
    • 16.3.2. Merck KGaA
    • 16.3.3. Sphere Fluidics Ltd.
    • 16.3.4. ViaCyte, Inc.
    • 16.3.5. Blacktrace Holdings Ltd. (Dolomite Microfluidics)
    • 16.3.6. BIO INX
    • 16.3.7. Living Cell Technologies Ltd.
    • 16.3.8. Sigilon Therapeutics, Inc.
    • 16.3.9. Isogen
    • 16.3.10. Diatranz Otsuka Ltd.
    • 16.3.11. Sernova Corporation
    • 16.3.12. Atelerix Ltd.
    • 16.3.13. Neurotech Pharmaceuticals
    • 16.3.14. Kadimastem
    • 16.3.15. BUCHI Labortechnik AG
    • 16.3.16. Fluigent
    • 16.3.17. Encapsys LLC
    • 16.3.18. MiKroCaps
    • 16.3.19. Reed Pacific Pty Limited
    • 16.3.20. Lycored

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MATERIAL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA LIVE CELL ENCAPSULATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. LIVE CELL ENCAPSULATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. LIVE CELL ENCAPSULATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LIVE CELL ENCAPSULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CANCER IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGENERATIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGENERATIVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGENERATIVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGENERATIVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGENERATIVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGENERATIVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INSULIN-PRODUCING CELL DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INSULIN-PRODUCING CELL DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INSULIN-PRODUCING CELL DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INSULIN-PRODUCING CELL DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INSULIN-PRODUCING CELL DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INSULIN-PRODUCING CELL DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELL TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELL TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELL TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELL TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELL TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELL TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TARGETED DRUG DELIVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TARGETED DRUG DELIVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TARGETED DRUG DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TARGETED DRUG DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TARGETED DRUG DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TARGETED DRUG DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BONE TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BONE TISSUE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BONE TISSUE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BONE TISSUE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BONE TISSUE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BONE TISSUE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARDIAC TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARDIAC TISSUE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARDIAC TISSUE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARDIAC TISSUE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARDIAC TISSUE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARDIAC TISSUE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARTILAGE TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARTILAGE TISSUE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARTILAGE TISSUE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARTILAGE TISSUE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARTILAGE TISSUE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CARTILAGE TISSUE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MACROENCAPSULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOLLOW FIBER DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOLLOW FIBER DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOLLOW FIBER DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOLLOW FIBER DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOLLOW FIBER DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOLLOW FIBER DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HYDROGEL SHEETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HYDROGEL SHEETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HYDROGEL SHEETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HYDROGEL SHEETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HYDROGEL SHEETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HYDROGEL SHEETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MICROENCAPSULATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EMULSION TECHNIQUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EMULSION TECHNIQUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EMULSION TECHNIQUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EMULSION TECHNIQUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EMULSION TECHNIQUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EMULSION TECHNIQUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EXTRUSION TECHNIQUE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EXTRUSION TECHNIQUE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EXTRUSION TECHNIQUE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EXTRUSION TECHNIQUE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EXTRUSION TECHNIQUE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY EXTRUSION TECHNIQUE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SPRAY DRYING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SPRAY DRYING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SPRAY DRYING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SPRAY DRYING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SPRAY DRYING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SPRAY DRYING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ALGINATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HIGH GELATION ALGINATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HIGH GELATION ALGINATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HIGH GELATION ALGINATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HIGH GELATION ALGINATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HIGH GELATION ALGINATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HIGH GELATION ALGINATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LOW GELATION ALGINATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LOW GELATION ALGINATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LOW GELATION ALGINATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LOW GELATION ALGINATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LOW GELATION ALGINATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LOW GELATION ALGINATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CHITOSAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CROSSLINKED CHITOSAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CROSSLINKED CHITOSAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CROSSLINKED CHITOSAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CROSSLINKED CHITOSAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CROSSLINKED CHITOSAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CROSSLINKED CHITOSAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DEACETYLATED CHITOSAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DEACETYLATED CHITOSAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DEACETYLATED CHITOSAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DEACETYLATED CHITOSAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DEACETYLATED CHITOSAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DEACETYLATED CHITOSAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COLLAGEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COLLAGEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COLLAGEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COLLAGEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COLLAGEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY COLLAGEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SYNTHETIC POLYMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SYNTHETIC POLYMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SYNTHETIC POLYMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SYNTHETIC POLYMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SYNTHETIC POLYMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY SYNTHETIC POLYMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY ISLET CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DONOR ISLET CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DONOR ISLET CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DONOR ISLET CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DONOR ISLET CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DONOR ISLET CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY DONOR ISLET CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELL DERIVED ISLET CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELL DERIVED ISLET CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELL DERIVED ISLET CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELL DERIVED ISLET CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELL DERIVED ISLET CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELL DERIVED ISLET CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY PROBIOTIC BACTERIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIFIDOBACTERIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIFIDOBACTERIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIFIDOBACTERIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIFIDOBACTERIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIFIDOBACTERIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY BIFIDOBACTERIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LACTOBACILLUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LACTOBACILLUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LACTOBACILLUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LACTOBACILLUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LACTOBACILLUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY LACTOBACILLUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY INDUCED PLURIPOTENT STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY MESENCHYMAL STEM CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL LIVE CELL ENCAPSULATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY DIABETES MANAGEMENT, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY DRUG DELIVERY, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY TISSUE ENGINEERING, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS LIVE CELL ENCAPSULATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS LIVE CELL ENCAPSUL